Updated:
Viva BioInnovator
Viva BioInnovator is a Shanghai-based venture firm investing in early-stage life sciences, bridging China's academic labs and global biotech markets.
Viva BioInnovator
Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer l
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Sector focus
Frequently asked questions
What investment stages does Viva BioInnovator typically target?
Viva BioInnovator targets seed-stage through growth-stage biotech investments. Its earliest entry points often involve translational funding before a company formally incorporates, supporting preclinical proof-of-concept studies at academic institutions. The firm also participates in later venture rounds as portfolio companies advance into clinical development.
How does Viva BioInnovator source proprietary deal flow?
The firm sources deal flow through deep relationships with China's top research universities and teaching hospitals. By embedding scientific evaluation at the academic bench level, Viva BioInnovator identifies promising drug targets and platform technologies before they reach competitive Series A auctions. This academic-origination model is a core sourcing advantage.
Which sectors does Viva BioInnovator explicitly focus on?
The firm invests primarily in biotechnology and digital health. Within biotech, the focus spans small molecule therapeutics, biologics, cell and gene therapies, and enabling platform technologies. Digital health investments center on AI-driven drug discovery, clinical trial analytics, and precision medicine tools.
Is Viva BioInnovator structured as a traditional venture capital firm?
Yes, Viva BioInnovator is structured as a private venture capital firm, but it operates an active company-creation model that resembles an institutional incubator. The firm originates and staffs new companies from academic research rather than only investing in externally founded startups.
Does Viva BioInnovator participate in fund commitments or only direct deals?
The firm is primarily a direct investor, making equity investments into early-stage biotech companies. There is no public evidence of a fund-of-funds program. Co-investments alongside other life sciences specialist funds have been observed in publicly disclosed financing rounds.
What is Viva BioInnovator's geographic investment mandate?
The firm's primary geographic mandate is China, with an emphasis on Shanghai-based research institutions and biotech clusters. An increasing number of portfolio interactions involve US- and Europe-headquartered biotech companies seeking to access Asian regulatory and commercial pathways.
Who runs investment decisions at Viva BioInnovator?
Investment decision-making structure is not publicly detailed. The firm maintains a research-driven investment committee staffed by scientific domain experts rather than generalist financial analysts, consistent with specialist biotech investors of this type.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: